Intra-Cellular Therapies (ITCI) News Today $131.28 +3.08 (+2.40%) Closing price 04:00 PM EasternExtended Trading$131.28 0.00 (0.00%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Intra-Cellular Therapies (NASDAQ:ITCI) Sees Large Volume Increase - Time to Buy?Intra-Cellular Therapies (NASDAQ:ITCI) Sees Strong Trading Volume - What's Next?March 3 at 3:38 PM | marketbeat.comIFP Advisors Inc Buys 2,348 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)IFP Advisors Inc grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 96.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,777 shares of the biopharmaceutical company's stock after acquiMarch 2 at 3:41 AM | marketbeat.comY Intercept Hong Kong Ltd Cuts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Y Intercept Hong Kong Ltd lessened its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 52.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,525 shares of the biophMarch 2 at 3:41 AM | marketbeat.comIntra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025March 1 at 5:04 PM | insidermonkey.comIntra-Cellular Therapies Target of Unusually High Options Trading (NASDAQ:ITCI)Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) saw some unusual options trading activity on Friday. Stock investors purchased 5,021 call options on the company. This is an increase of 380% compared to the typical volume of 1,046 call options.March 1 at 11:47 AM | marketbeat.comGW&K Investment Management LLC Sells 6,734 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)GW&K Investment Management LLC decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,387,462 shares of theMarch 1 at 6:41 AM | marketbeat.comIntra-Cellular Therapies Sees Unusually Large Options Volume (NASDAQ:ITCI)March 1 at 2:57 AM | americanbankingnews.com2,622 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Wealthspire Advisors LLCWealthspire Advisors LLC acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,622 shares of the biopharmaceutical company's stock, valued at approximatFebruary 28 at 3:57 AM | marketbeat.comCantor Fitzgerald Brokers Lower Earnings Estimates for ITCIFebruary 28 at 3:13 AM | americanbankingnews.comPhocas Financial Corp. Sells 16,348 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Phocas Financial Corp. trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 85.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,885 shares of the biopharmaceutical companyFebruary 27, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by New York State Common Retirement FundNew York State Common Retirement Fund boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,February 27, 2025 | marketbeat.comKuehn Law Encourages Investors of Intra-Cellular Therapies, Inc. to Contact Law FirmFebruary 26, 2025 | investing.comIntra-Cellular Therapies (NASDAQ:ITCI) Reaches New 12-Month High - Still a Buy?Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 52-Week High - Here's WhyFebruary 26, 2025 | marketbeat.comCantor Fitzgerald Has Weak Outlook for ITCI FY2025 EarningsIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Intra-Cellular Therapies in a report released on Monday, February 24th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmacFebruary 26, 2025 | marketbeat.comMizuho Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to NeutralFebruary 26, 2025 | americanbankingnews.comINTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCIFebruary 25, 2025 | businesswire.comIntra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.comFebruary 25, 2025 | americanbankingnews.comIntra-Cellular downgraded to Neutral from Outperform at MizuhoFebruary 24, 2025 | markets.businessinsider.comMizuho Downgrades Intra-Cellular Therapies (ITCI)February 24, 2025 | msn.comITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to ShareholdersFebruary 24, 2025 | businesswire.comIntra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by MizuhoMizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $140.00 to $132.00 in a research report on Monday.February 24, 2025 | marketbeat.comHealthInvest Partners AB Reduces Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)HealthInvest Partners AB cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 15.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,138 shares of the biopharmaceutical company's stock after selliFebruary 24, 2025 | marketbeat.comING Groep NV Acquires New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)ING Groep NV acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,500 shares of the biopharmaceutical company's stock, valued atFebruary 24, 2025 | marketbeat.comIntra-Cellular Therapies' (ITCI) Hold Rating Reiterated at Needham & Company LLCFebruary 24, 2025 | americanbankingnews.comStockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Monday. They set a "hold" rating on the stock.February 24, 2025 | marketbeat.comIeq Capital LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Ieq Capital LLC boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 469.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,398 shares of the biopharmaceutical company'sFebruary 23, 2025 | marketbeat.comAlberta Investment Management Corp Sells 4,500 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Alberta Investment Management Corp lowered its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 46.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,100 shares of the biopharmaceutical company's sFebruary 23, 2025 | marketbeat.comTitle: Intra-Cellular Therapies Reveals Year-End Unaudited Financials, Caplyta’s Remarkable Performance Key HighlightFebruary 23, 2025 | americanbankingnews.comIntra-Cellular Therapies Inc (ITCI) Reports Strong Financial Growth and Pipeline AdvancementsFebruary 23, 2025 | gurufocus.comIntra-Cellular Therapies (NASDAQ:ITCI) Given "Hold" Rating at Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday.February 22, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPSIntra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) announced its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%.February 22, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Raises Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Allspring Global Investments Holdings LLC increased its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1,443.5% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 28,631 shares of the biopharmaceutical company's stock after buying anFebruary 22, 2025 | marketbeat.comIntra-Cellular reports Q4 EPS (16c), consensus (11c)February 21, 2025 | markets.businessinsider.comHold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition ProspectsFebruary 21, 2025 | tipranks.comIntra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 21, 2025 | investing.comIntra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 21, 2025 | globenewswire.comPrincipal Financial Group Inc. Reduces Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Principal Financial Group Inc. decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 7.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 550,963 shares of the biopharmaceutical company's stock aFebruary 21, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month High - What's Next?Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month High - Should You Buy?February 20, 2025 | marketbeat.comIntra-Cellular Therapies (ITCI) Expected to Announce Earnings on ThursdayIntra-Cellular Therapies (NASDAQ:ITCI) will be releasing earnings before the market opens on Thursday, February 27.February 20, 2025 | marketbeat.comTimesSquare Capital Management LLC Buys 402,186 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)TimesSquare Capital Management LLC boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 91.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 840,269 shares of theFebruary 19, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 6.7% in JanuaryIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 1,600,000 shares, an increase of 6.7% from the January 15th total of 1,500,000 shares. Based on an average trading volume of 2,270,000 shares, the short-interest ratio is presently 0.7 days.February 17, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Savant Capital LLCSavant Capital LLC decreased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 55.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,222 shares of the biopharmaceutical compFebruary 17, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLCQuantum Private Wealth LLC trimmed its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 22.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 30,142 shares of the biopharmaceutical company's stock after selling 8,519 shares duringFebruary 16, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated by Analysts at StockNews.comStockNews.com began coverage on Intra-Cellular Therapies in a report on Sunday. They issued a "hold" rating for the company.February 16, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High - Here's WhyIntra-Cellular Therapies (NASDAQ:ITCI) Sets New 52-Week High - What's Next?February 14, 2025 | marketbeat.comIntra-Cellular Therapies Stock Soars to All-Time High of $128.01February 13, 2025 | msn.comLegato Capital Management LLC Has $2.45 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Legato Capital Management LLC grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 48.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,364 shares of the biopharmaceutical company'February 12, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Shares Unloaded Rep. Josh GottheimerRepresentative Josh Gottheimer (D-New Jersey) recently sold shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). In a filing disclosed on February 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intra-Cellular Therapies stock on January 24th. The trade occurreFebruary 12, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, six have issuedFebruary 8, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.comStockNews.com began coverage on Intra-Cellular Therapies in a research note on Saturday. They set a "hold" rating on the stock.February 8, 2025 | marketbeat.com Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Media Mentions By Week ITCI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITCI News Sentiment▼0.490.70▲Average Medical News Sentiment ITCI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITCI Articles This Week▼268▲ITCI Articles Average Week Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TAK News ARGX News BNTX News ONC News TEVA News GMAB News SMMT News MRNA News VTRS News RDY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITCI) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
